Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Novartis is turning to biodegradable drug-delivery materials to boost its cancer vaccine programs. The Swiss company will work with implantable or injectable materials for cancer immunotherapy developed by scientists from Dana-Farber Cancer Institute and Harvard University’s Wyss Institute. Glenn Dranoff, Novartis’s head of immuno-oncology, says the materials are porous and filled with compounds that prime immune cells to target tumors. Dranoff previously worked on them while at Dana-Farber.
This article has been sent to the following recipient: